An analysis of the Systolic Blood Pressure Intervention Trial (SPRINT) indicates that nearly all adults with chronic kidney disease (CKD) would have benefits that outweigh the harm from a systolic blood pressure target of <120 mm Hg compared with a target of <140 mm Hg. The findings will be presented at ASN Kidney Week 2025 November 5– 9.
To continue reading click here
